Abstract:DEAR EDITOR, Enlarged pores are a common cosmetic concern. Although nonablative fractional lasers (NAFLs) have been used to reduce enlarged facial pores, a prospective, split-face, controlled study with objective assessment is lacking. A 1565-nm NAFL (M22 ResurFX; Lumenis, Yokneam, Israel) has proved effective on skin elasticity and stretch marks; therefore, we aimed to assess its safety and efficacy on enlarged facial pores. The present study was approved by the investigational review board of the Shanghai Ninth People’s Hospital (clinical trials registration number ChiCTR-ONh-16009094). We initially estimated an improvement of 40% on the treated side of the face vs. the nontreated side. To estimate sample size, we tested the null hypothesis that there would be a decrease of ≤ 10% in the number of enlarged pores between both sides of the face. With a sample size of 17, a 40% difference between the two sides would refute this hypothesis with a power of 80% and a 2 5% level of significance. In total, 22 participants with increased seborrhoea and enlarged pores were enrolled. Seventeen patients completed the study and five dropped out. Complaints of pain or oedema and personal reasons accounted for the dropouts. Based on a computer-generated randomization list, one side of the face was treated and the other side served as the control (Fig. 1a; further images are available from the corresponding author upon request). EMLA (Astra Pharmaceuticals, Oslo, Norway), a topical anaesthetic ointment (containing 25 mg lidocaine and 25 mg prilocaine), was applied 1 h before treatment. Spots measuring 17 mm with integrated contact cooling were used. A 38–40 mJ per microbeam laser was used for the first pass and 20–24 mJ per microbeam for the second; density was 300 microbeams per cm for both passes. The same parameters were used for a total of four treatments carried out at 2-week intervals. The quantitative number of pores was automatically calculated with the VISIA-CR imaging system (Canfield Scientific, Fairfield, NJ, U.S.A.) before treatment and 2 months after the final treatment. The device detects pores using an algorithm designed to detect circular objects of 0 4–1 0 mm in diameter. Feature analysis only occurs within automatically targeted zonal mask regions representing the best view, thereby reducing variability due to the camera angle. Use of the NAFL significantly decreased the number of facial pores (P < 0.001) post-treatment. The total average number of facial pores was 1015 on the NAFL-treated side and 1012 on the untreated side; these numbers decreased to 631 and 848, respectively, at the 2-month follow-up. The average pore reduction rate was 41 1% for the NAFL side and 16 5% for the untreated side (Fig. 1b–f). Missing data were not included. Participants were asked to rate the degree of pain immediately post-treatment using a visual analogue scale (VAS) ranging from 0 (no pain at all) to 10 (unbearable pain). Pain was reported as mild to moderate with a mean SD VAS score of 4 75 1 23. Other adverse events included immediate slightto-moderate erythema and oedema (100%), which continued for 2–4 days post-treatment. No permanent side-effects were seen. Compared with traditional ablative procedures, such as the CO2 fractional laser or the erbium–yttrium aluminum garnet fractional laser, NAFL allows for quicker healing with minimal downtime, low treatment discomfort and relatively fewer side-effects. Enlarged pores have been treated with an increasing focus on increased seborrhoea rather than as a component of photoageing. Only mild improvement of facial pores has been observed using a 1064-nm neodymium-doped yttrium aluminum garnet laser. Recently, NAFLs were introduced for skin resurfacing. Compared with the 1550/1540-nm laser, the 1565-nm NAFL has similar water absorption features. However, the newest CoolScan technique, as well as its integrated contact cooling system, has limited the bulk heating to the dermis, making it safer for sensitive or darker skin than other NAFLs. The ‘bystander effect’ may have contributed to the decrease of pores on the untreated side of the face. In the absence of any direct heating, heat diffusion or cell-to-cell contact, ‘bystander’ cells experience DNA damage, apoptosis and loss of viability when sharing the medium with heat-exposed cells. This is mostly found in dividing cells. We hypothesize that both bystander effects and an improvement in patient lifestyle contributed to skin resurfacing on the untreated sides of the face. The present study is the first split-face controlled trial using a 1565-nm NAFL with objective measurements for treating facial pores. Limitations include the low number of participants and the relatively brief follow-up period. The preliminary data show that a 1565-nm NAFL is significantly effective

Updates on laser and aesthetic medicine (2020-2021)

Effectiveness and Safety of Nonablative Fractional Laser and Infrared Bipolar Radiofrequency for Treating Periorbital Wrinkles

Efficacy and safety of 1565-nm non-ablative fractional laser versus long-pulsed 1064-nm Nd:YAG laser in treating enlarged facial pores

Effectiveness and safety of nonablative fractional laser and infrared bipolar radiofrequency on periorbital wrinkles: a randomized self-controlled trial

An optimized intense pulsed light combined with a non-ablative 1 565 nm fractional laser for facial rejuvenation: a randomized, controlled, split-face study

Hyaluronic Acid Dissolving Microneedles and Nonablative Fractional Laser for Infraorbital Wrinkles: A Prospective, Randomized, Split-Face Study

The clinical observation of 1100~1800 nm broad band infrared intense pulsed light for the treatment of periorbital wrinkle

Fractional microneedle radiofrequency device and fractional erbium-doped glass 1,565-nm device treatment of human facial photoaging: a prospective, split-face, random clinical trial

Efficacy of focused radiofrequency in facial wrinkle and laxity

Periocular rejuvenation using a unique non-ablative long-pulse 2940 nm Er:YAG laser

The Efficacy and Safety of Radiofrequency Microneedling Versus a Nonablative Fractional 1,550-nm Erbium:Glass Laser for the Rejuvenation of the Neck

A prospective, randomized, double-blind comparison of an ablative fractional 2940-nm erbium-doped yttrium aluminum garnet laser with a nonablative fractional 1550-nm erbium-doped glass laser for the treatment of photoaged Asian skin

Curative effects of microneedle fractional radiofrequency system on skin laxity in Asian patients: A prospective, double-blind, randomized, controlled face-split study

Efficacy of fractional laser, radiofrequency and IPL rejuvenation of periorbital region

Clinical Assessment of Non-ablative Fractional Laser Combined with Transdermal Delivery of Botulinum Toxin A in Treating Periocular Wrinkles

Comparison of fractionated frequency-doubled 1,064/532 nm picosecond Nd:YAG lasers and non-ablative fractional 1,540 nm Er: glass in the treatment of facial atrophic scars: a randomized, split-face, double-blind trial

Use of a fractional 1570‐nm diode laser scanner for non‐ablative face and neck rejuvenation

Full‐face and neck resurfacing with a novel ablative fractional 2910 nm erbium‐doped fluoride glass fiber laser for advanced photoaging

Randomized Split-Face, Controlled Comparison of Treatment with 1565-Nm Nonablative Fractional Laser for Enlarged Facial Pores

Clinical Efficacy and Safety of a Focused-Radiofrequency Device on Middle and Lower Face Rejuvenation: a Retrospective Clinical Study.

Comparison of 1064-nm Nd:YAG picosecond laser using fractional micro-lens array vs. ablative fractional 2940-nm Er:YAG laser for the treatment of atrophic acne scar in Asians: a 20-week prospective, randomized, split-face, controlled pilot study